Joel Lewis - Jan 23, 2025 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
President and CEO, Director
Signature
Jack W. Callicutt, by power of attorney
Stock symbol
GALT
Transactions as of
Jan 23, 2025
Transactions value $
$0
Form type
4
Date filed
1/27/2025, 04:06 PM
Previous filing
Dec 26, 2024
Next filing
Mar 5, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +91K $0.00 91K Jan 23, 2025 Common Stock 91K $1.23 Direct F1, F2
transaction GALT Restricted Stock Unit Award $0 +84K $0.00 84K Jan 23, 2025 Common Stock 84K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026.
F3 The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.
F4 Restricted Stock Units vest upon the earlier of December 31, 2025 or signing a partnership agreement.